Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$28.49+0.62 (+2.22%)
Close on Nov 17, 2026Market cap $4.55BP/E –Yield –
Adaptive Biotechnologies price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Adaptive Biotechnologies's price to sales ratio was 15.5× on Nov 11, 2026, against 11.9× a year earlier. Over the last 5 years it ranged from 2.2× to 27.0×, with a median of 7.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 15.5× | +5.7 |
| 2025 | Dec 31, 2025 | 9.8× | +4.8 |
| 2024 | Dec 31, 2024 | 5.0× | +1.0 |
| 2023 | Dec 29, 2023 | 3.9× | −2.6 |
| 2022 | Dec 30, 2022 | 6.5× | −20.5 |
| 2021 | Dec 31, 2021 | 27.0× | −60.3 |
| 2020 | Dec 31, 2020 | 87.3× | +39.6 |
| 2019 | Dec 31, 2019 | 47.7× | – |
See a number that looks wrong?